Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Thomas Kosh

Physician Assistant Rowlett, TX Physician Assistant

NPI 1881061208 CMS profile 10516629

9100 Lakeview Pkwy, Rowlett, TX 75088

Open in the dashboard

General payments

$11,023

349 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Kosh of Rowlett, TX is reported in the CMS Open Payments database as having received $11,023 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,033 86
2024 General $4,109 144
2023 General $2,387 76
2022 General $1,243 40
2021 General $251 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Kosh
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Thomas Kosh were reported at $3,033. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Thomas Kosh Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $251 $132 $37–$438 $132
2022 $1,243 $155 $48–$522 $149
2023 $2,387 $167 $52–$557 $160
2024 $4,109 $178 $55–$600 $164
2025 $3,033 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $2,498 43 payments
  2. AstraZeneca Pharmaceuticals LP $859 26 payments
  3. Janssen Biotech, Inc. $776 21 payments
  4. Daiichi Sankyo Inc. $774 31 payments
  5. Pfizer Inc. $372 17 payments
  6. E.R. Squibb & Sons, L.L.C. $364 18 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $350 15 payments
  8. Gilead Sciences, Inc. $251 12 payments
  9. Merck Sharp & Dohme Corporation $241 10 payments
  10. Sobi, Inc $238 6 payments
  11. Other $4,301 150 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,084 314 payments
  2. Long term medical supply or device loan $2,165 25 payments
  3. Education $774 10 payments
Products named General payments · program years 2021–2025
  1. KISQALI $2,207 33 payments
  2. ENHERTU Oncology $657 21 payments
  3. IMFINZI $415 12 payments
  4. ERLEADA $311 8 payments
  5. OPDIVO $282 14 payments
  6. IMBRUVICA $280 6 payments
  7. BESREMI $233 7 payments
  8. Nubeqa $226 10 payments
  9. KEYTRUDA $208 9 payments
  10. ENHERTU Oncology $207 8 payments
  11. Other $7,013 275 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

764

Median for Physician Assistant: 241

Drug cost

$45,437

Median for Physician Assistant: $4,110

Branded share of claims

30%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 40 $26,092
Eliquis Apixaban Brand 12 $6,612
Enoxaparin Sodium Generic 22 $4,891
Ondansetron Odt Ondansetron Brand 104 $1,711
Dexamethasone Generic 29 $991
Acyclovir Generic 50 $758
Olanzapine Generic 53 $673
Tramadol Hcl Generic 44 $368
Zolpidem Tartrate Generic 47 $352
Mirtazapine Generic 35 $351

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$116,041

Of which drugs: $33,882

Medicare patients

275

Average age 75

Services billed

5,914

145 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Cancer 39%
Chronic kidney disease 37%
Diabetes 34%
Depression 30%
Ischemic heart disease 26%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 66 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $1,150
$1,150 — —
ENHERTU
  • Daiichi Sankyo Inc. $128
  • AstraZeneca Pharmaceuticals LP $80
$208 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $148
$148 — —
BESREMI
  • PharmaEssentia USA Corporation $130
$130 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $116
$116 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 66 with Patron

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record